MMSI Merit Medical Systems Inc.

Merit Medical Celebrates Completion of Xeriscape Landscaping Project

Merit Medical Celebrates Completion of Xeriscape Landscaping Project

Utah Governor and local officials joined Merit in recognizing green initiative to save 4 million gallons of water each year

SOUTH JORDAN, Utah, June 29, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today celebrated the completion of a xeriscape landscaping project at its South Jordan headquarters with Utah Governor Spencer J. Cox. Nearly three acres of grass has been replaced, reducing water intensive plantings by approximately 75%. More than 1,142 tons of decorative rock, 250 boulders, along with native drought-resistant, low-water plants and shrubs have been installed. All existing trees remained intact and 56 have been added. The project included a new drip irrigation system designed to prevent water evaporation and runoff.

“Merit takes corporate citizenship seriously,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “Our xeriscaping initiative is one of several projects Merit is undertaking to reduce our environmental impact. Utah’s drought conditions make the need to protect our water resources urgent, and Merit is excited to be part of the solution.”

South Jordan Mayor Dawn Ramsey reiterated the urgent need to save water. “South Jordan has citywide initiatives to make our community eco-friendlier,” she added. “Merit’s xeriscaping initiative helps to protect Utah’s natural resources and supports our community’s needs. The positive feedback and appreciation we have received from the South Jordan community has been phenomenal.”

In 2016, the Utah Division of Water Resources launched the H2Oath: a waterwise pledge to encourage practical and efficient water conservation efforts by families, businesses, cities, government agencies, and statewide organizations. “Thousands of people and organizations have taken the H2Oath,” stated Utah Governor Spencer J. Cox. “Merit’s xeriscaping initiative is an example of a company doing what is right. This progress is encouraging, and I hope others continue to follow their example.”  

ABOUT MERIT MEDICAL  

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.  

  

TRADEMARKS  

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.  

  

CONTACTS   

PR/Media Inquiries   

Sarah Comstock  

Merit Medical   

|   

   

INVESTOR INQUIRIES   

Mike Piccinino, CFA, IRC   

Westwicke - ICR   

|    



EN
29/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Acquires Biolife Delaware, L.L.C. Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acq...

 PRESS RELEASE

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-I...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulator...

 PRESS RELEASE

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Ar...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium ...

 PRESS RELEASE

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year...

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch